CDTX News and Press, Cidara Therapeutics Inc. From 12/14/21

The decline in Cidara Therapeutics (CDTX -31.0%) that began premarket following the release of top-line data on its phase 3 antifungal candidate rezafungin has continued to widen. Shares are dropping even though the trial met FDA and EMA pre-specified primary endpoints. Earlier this...

Gainers: Galera Therapeutics (NASDAQ:GRTX) +106%. Nuverra Environmental Solutions (NYSE:NES) +33%. CPS Technologies (NASDAQ:CPSH) +24%. Terminix (NYSE:TMX) +21%. Alzamend Neuro (NASDAQ:ALZN) +17%. MIND Technology (NASDAQ:MIND) +17%. Landec Corporation (NASDAQ:LNDC) +13%. Soliton (NASDAQ:SOLY)...

Gainers: Galera Therapeutics (NASDAQ:GRTX) +116%, Alzamend Neuro (NASDAQ:ALZN) +18%, Soliton (NASDAQ:SOLY) +12%, Kiromic BioPharma (NASDAQ:KRBP) +6%, Biofrontera (NASDAQ:BFRI) +5%. Losers: Adagio Therapeutics (NASDAQ:ADGI) -78%, Adagio Th...

Adagio Therapeutics (NASDAQ:ADGI) -67% after Omicron led to 300-fold reduction in neutralizing effect in COVID-19 therapy. Aptose Biosciences (NASDAQ:APTO) -32% following ASH data on acute myeloid leukemia candidate. SeaChange International (NASDAQ:SEAC) -22%. Mesoblast (N...

Cidara Therapeutics (NASDAQ:CDTX) announces positive topline data from the Phase 3 ReSTORE trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential first-line treatment for candidemia and invasive candidiasis. Shares down 4.9% premar...

Trial met FDA and EMA-pre-specified primary endpoints versus daily standard of care Data to support global regulatory filings in mid-2022 Cidara to host investor conference call today, December 14th, at 8:30 a.m. EST to provide further details on the data SAN DIEGO a...

The stock market is getting smoked today, and many penny stocks haven’t been immune to this either. Shocking jobs figures reported during premarket hours added to growing concerns. On Friday, the November jobs report showed that just 210,000 jobs were added last month. This didn&...

SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it has been named a Top Workplace by ...

Cidara Therapeutics (NASDAQ:CDTX): Q3 GAAP EPS of -$0.37 misses by $0.02. Revenue of $7.08M (+192.6% Y/Y) beats by $4.14M. Press Release For further details see: Cidara Therapeutics EPS misses by $0.02, beats on revenue

SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended Sept...